BMO Capital analyst Etzer Darout raised the firm’s price target on Acrivon Therapeutics to $25 from $18 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company’s demonstration of proof-of-concept for its platform with initial data for ACR-368 in patients with ovarian and bladder cancers, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics Inc trading halted, volatility trading pause
- Acrivon Therapeutics price target raised to $30 from $26 at Piper Sandler
- Acrivon Therapeutics price target raised to $17 from $14 at JMP Securities
- Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
- Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event